Salus Scientific Closes Oversubscribed Series A Financing, Raising $10.1 Million
Salus Scientific Closes Oversubscribed Series A Financing, Raising $10.1 Million
PR Newswire
CHARLESTON, S.C., Aug. 5, 2026
CHARLESTON, S.C., Aug. 5, 2026 /PRNewswire/ -- Salus Scientific today announced the successful closing of its oversubscribed Series A financing, raising a total of $10.1 million. The company entered the round targeting $8.0 million, but investor demand proved substantially stronger, and the round closed above target and ahead of schedule.
The new capital gives Salus a durable runway to fund commercial scale-up, expand its production and clinical infrastructure, and carry the company through its revenue ramp.
"We are pleased to have closed our Series A above target and ahead of schedule," said Todd Flohr, Chairman and Chief Executive Officer of Salus Scientific. "We are thrilled to welcome partners who understand our value proposition and align with the company's long-term vision. That the round closed oversubscribed is, in our view, a direct endorsement of both our commercial thesis and our execution discipline."
About Salus Scientific
Salus Scientific is building the occupational wellness platform for modern procedural medicine, redefining how healthcare organizations protect the physicians, technologists, and nurses who perform fluoroscopy-guided procedures.
Media & Investor Contact
Keith Rosmarin
Chief Financial Officer
Keith.rosmarin@salusscientific.com
Forward-Looking Statements: This press release contains "forward-looking statements," including statements regarding the company's use of proceeds, growth strategy, and future capital requirements. These statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. The company undertakes no obligation to update forward-looking statements except as required by applicable law.
SOURCE Salus Scientific
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Invest In With More Room to Run
United States